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INTRODUCTION
Some patients with large-angle strabismus may refuse or
may not meet the criteria for binocular surgical correction. A
second option for these patients involves a monocular
procedure, which can be performed under peribulbar
anesthesia and offers certain advantages (1).
Improved surgical outcomes for conventional procedures
may enhance the effectiveness of monocular surgery. In
theory, this enhancement could be achieved by the
coadjuvant use of intraoperative botulinum toxin A (BT)
(2). To date, few reports have described the intraoperative
injection of BT (3-5).
Owens et al. (3) performed supramaximal monocular
recession-resection surgeries and successfully used intrao-
perative BT in three large-angle exotropia patients. Khan (4)
successfully performed two-muscle horizontal rectus sur-
gery with simultaneous BT injection in patients with severe
large-angle esotropia. Additionally, seven patients under-
went bilateral medial rectus recession and bilateral BT
injection, and one patient underwent a unilateral recess/
resection surgery with medial rectus BT injection. These
results indicated that bilateral medial rectus recession with
simultaneous BT injection is a safe and effective surgical
procedure for patients with severe large-angle esotropia,
although more extensive studies are required to confirm
these findings. O¨skan et al. (5) reported the results of 10
patients with large-angle horizontal deviations (eso- or
exotropia) who received BT injections into one recessed
muscle and concluded that such treatment may provide
greater surgical success compared to conventional horizon-
tal rectus muscle surgeries.
The results of these uncontrolled studies have reinforced
the hypothesis that long-term realignment of the eyes can be
achieved with surgery plus BT administration. However,
the effectiveness of the addition of intraoperative BT
compared to surgery alone is unclear.
In this pilot study, we used a prospective, controlled, and
randomized double-blind methodology to examine the
effectiveness of BT injection in combination with surgical
treatment compared to surgical treatment alone for the
correction of large-angle horizontal deviations under local
anesthesia.
PATIENTS AND METHODS
The study population was composed of adult patients 18
years of age or older who had concomitant horizontal
deviations (eso- or exotropia) of 50 pd or more. Patients who
had undergone previous surgical treatment or who had
neurological or systemic disease, oblique muscle dysfunc-
tion, dissociated vertical deviations or other clinically
significant vertical deviations, or paretic or restrictive
strabismus were excluded from the study.
The preliminary information that was recorded for each
patient included the age at which strabismus was detected
and diagnosed, the best-corrected visual acuity (BCVA), the
frequency of severe amblyopia (BCVA less than 0.5 without
other anatomical eye abnormalities), the angle of deviation
before treatment, the surgical plan (mm of recess/resection),
and the surgery ratio (angle of pretreatment deviation
divided by the sum of mm of recess plus mm of resection).
Snellen visual acuity was converted to LogMAR acuity prior
to statistical analysis (6) and then converted back to the
Snellen equivalent.
The study was designed to include 11 patients in each
group. This sample size was chosen based on previously
published reports of monocular recess/resection surgeries
for the correction of horizontal strabismus (1).
The patients were randomized to the surgery plus hyaline
solution (SG) treatment group or to the surgery plus
botulinum toxin-A (SG+BT) treatment group. The investi-
gators were blinded to the patients’ treatment groups.
All of the patients underwent a complete ophthalmologi-
cal and motor evaluation prior to surgery. The angles of
deviation were measured with the best optical correction in
place for the distance and the near and cardinal gaze
positions. The measurements were made using the simulta-
neous- and alternate-cover tests, and the Krimsky test was
employed when the cover tests were not applicable.
The surgeries were performed between November 2006
and June 2007 by the main investigator. The patients
underwent recess/resection surgeries on the non-fixating
eye using conventional techniques (7) under local anesthe-
sia. All patients received 5 mg of oral diazepam 30 minutes
before anesthesia. An intravenous line, oxygen nasal
cannula, cardiac monitoring and continuous pulse oximetry
were employed during the surgeries. The local anesthetic
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consisted of 0.5% bupivacaine without epinephrine and 2%
lidocaine with epinephrine. The extent of surgical recess/
resection was determined based on typical read-out values
(Table 1). Before reattaching the recessed muscle to the sclera,
the surgeon injected the posterior muscle belly with 0.1 ml of
hyaline solution alone (SG) or 5 units of BT (ProsignR,
Crista´lia, Campinas, Brazil) in 0.1 ml of hyaline solution
(SG+BT). The surgeon was unaware of the contents of each
syringe.
The outcome data were collected by the main investiga-
tor, who was unaware of the treatment assignment, except
in cases where ptosis had occurred. Angles of deviation
were measured one day, two weeks, one month, three
months, and 6-12 months (last visit) after the surgical
intervention, and any adverse effects were recorded.
The percent net changes in the deviations [(preoperative
deviation - postoperative deviation) 4 preoperative devia-
tion6100] were compared between groups at one day, two
weeks, one month, three months, and 6-12 months after
treatment. The percent net changes were also analyzed over
time by comparing the values for the first and last
postoperative visits between groups. There were not
separate strata for patients with esotropia and those with
exotropia.
The Mann-Whitney test was used to evaluate the
differences between the mean values of continuous data,
and Fisher’s exact test was used to compare percentages. An
analysis of variance (ANOVA) with rank transformation
was used to analyze the evolution of percent net change. All
data analyses and statistical comparisons were performed
using the SAS (Statistical Analysis System) software for
Windows (version 9.1.3) and Microcal Origin (version 5.0).
The level of significance was set at 5%, i.e., for p-
values#0.05).
This study was approved by the Ethics Committee of
the Faculty of Medical Sciences at the State University
of Campinas and complied with the principles of the
Declaration of Helsinki (8). Informed consent was obtained
from each patient who participated in the study.
RESULTS
Twenty-three patients underwent operations; of these, 12
patients (6 females and 6 males) were assigned to the SG+BT
group, and 11 patients (6 female and 5 males) were assigned
to the SG group. Table 1 summarizes the descriptive
variables for the two groups.
Table 2 presents the values of visual acuity, the pretreat-
ment deviation angles, the amount of recess-resection, and
the residual deviation for every patient included in the
study.
Table 1 - Summary of descriptive characteristics of the patients.
SG+BT SG
N=12 N=11 p- value
Age at surgery (years)* 34.3¡6.4 28.8¡9.8 0.08
Angle of preoperative deviation in pd* 65.8¡14.9 60.0¡16.9 0.27
Surgery ratio (pd of preop dev/mm of surgery)* 4.26¡0.85 3.86¡0.92 0.16
Fixating eye BCVA (LogMAR)* 0.08¡0.29 0.11¡0.30 0.53
Non-fixating eye BCVA (LogMAR)* 0.87¡0.76 1.03¡1.14 0.93
Non-fixating eye BCVA (0.5 or worse; LogMAR)* 1.15¡0.67 1.57¡1.10 0.42
Percentage of severe amblyopia (BCVA $0.5) 0.67 0.5 0.66
Fixating eye BCVA (decimal)** 0.9 0.8
Non-fixating eye BCVA (decimal)** 0.1 0.1
Non-fixating eye BCVA (0.5 or worse; decimal)** 0.07 0.03
*mean ¡ SD.
**mean values.
BCVA = best corrected visual acuity.
Pd = prism diopter.
BT = botulinum toxin.
SG = surgery.
Table 2 - Numerical data for the variables.
BCVA -
OD/OS
Initial
deviation
Recess-
resection Final deviation
SG+BT (dp) (mm) (dp)
1 1.0/0.1 XT 90 9 - 8 XT 15
2 1.0/0.3 XT 60 8 - 6 0
3 1.0/CF ET 85 7 - 9 ET 15
4 1.0/1.0 XT 60 9 - 8 XT 25
5 0.1/1.0 ET 80 7 - 9 ET 15
6 1.0/0.8 XT 50 8 - 8 XT 10
7 1.0/0.3 ET 50 6 - 8 0
8 0.5/1.0 XT 50 8 - 7 XT 12
9 0.15/1.0 ET 70 7 - 8 *
10 1.0/CF XT 80 9 - 7 XT 40
11 1.0/1.0 ET 65 7 - 9 *
12 CF/1.0 ET 50 6 - 8 ET 8
SG
1 1.0/1.0 XT 50 8 - 7 XT 5
2 1.0/CF XT 50 9 - 6 XT 15
3 0.1/0.1 XT 65 9 - 7 XT 15
4 1.0/1.0 XT 50 8 - 8 XT 6
5 1.0/0.1 XT 50 9 - 7 XT 15
6 1.0/0.2 ET 50 6 - 8 ET 15
7 0.9/1.0 ET 90 7 - 9 ET 40
8 1.0/CF XT 50 8 - 7 XT 35
9 0.7/0.5 XT 50 9 - 6 XT 20
10 1.0/CF ET 60 7 - 8 ET 15
11 1.0/0.6 ET 95 7 -10 ET 25
SG = surgery only.
SG+BT = surgery with botulinum toxin injection.
BCVA = Best-corrected Snellen visual acuity.
CF = count fingers.
XT = exotropia.
ET = esotropia.
Mm = millimeters.
Pd = prism diopter.
*Missing values.
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Six patients in the SG+BT group had esotropia, four of
which had presumably infantile esotropia and two had
partially accommodative esotropia. Of the six patients with
exotropia in this group, four had basic exotropia and two
had sensory exotropia. In the SG group, there were four
patients with esotropia, and each of these patients had
presumed infantile esotropia. Of the seven patients in this
group with exotropia, four had basic exotropia and three
had sensory exotropia.
The percent net changes in postoperative deviations
during the follow-up periods are shown in Table 3. These
values were only significantly different between the groups
at the one-month postoperative visit (p= 0.05), when
patients in the SG+BT group exhibited a larger percent net
change in their deviations than did the control patients. A
comparison of the results between the first and last follow-
up visits revealed a significant decrease in the percent net
change in both groups (p= 0.0001), but there was no
difference between the two groups (p= 0.59).
Ten of the 12 patients in the SG+BT group attended the
final follow-up visit at 6-12 months post-surgery. Eight of
these patients exhibited satisfactory results, and four of
these demonstrated orthotropia within 8 pd. The remaining
two patients had unsatisfactory results and underwent a
secondary operation. All eleven patients in the SG group
attended the final follow-up visit at 6-12 months post-
surgery. Seven of these patients had satisfactory results, and
two of these demonstrated orthotropia within 8 pd. The
results were unsatisfactory (more than 15 pd) for the
remaining four patients in this group (Table 1).
Transient ptosis was observed in 5 of the 12 patients in
the SG+BT group, and temporary vertical deviation was
observed in one patient. No patients suffered from adverse
effects related to surgery or anesthesia in the SG group.
Furthermore, no patients demonstrated fusion or diplopia at
the last follow-up visit.
DISCUSSION
In this study, we compared the results of surgery alone
versus surgery plus treatment with BT for the correction of
strabismus. Although there was a significant increase in the
percent net change in the deviations between 7 and 30 days
post-BT injection, this effect did not persist longer than three
months. In addition, both groups exhibited similar de-
creases in the percent net change of the first post-operative
measurement compared to the measurement at the final
visit.
As all of the participants in this study were adults and
demonstrated no evidence of fusion, the misalignment
corrections were performed mainly for psychosocial benefit.
The overall rate of surgical success was considered
satisfactory, as 72% of the patients exhibited final deviations
less than or equal to 15 pd.
BT can have a transient effect on extraocular muscles (9).
Additionally, as noted elsewhere (10), in the absence of
sensory and motor binocularity, there is a strong tendency
for the recurrence of deviations in BT-treated patients, and
this was also observed in our study. However, it is likely
that BT treatment may alter long-term ocular alignment in
children with fusion potential (11,12).
Certain studies have suggested a long-term, adjunctive
effect of BT administration on surgical outcome, even in
patients without fusion (3-5). Owens et al. (3) observed stable
orthotropia at 2.5 years, stable 8-pd exotropia at 4 years, and
stable 18-pd exotropia at 7 months in his case series of 3
patients. O¨skan et al. (5) described the results for 10 patients
(three children and seven adults with no preoperative fusion)
with large-angle esotropia and exotropia who were treated
intraoperatively with BT during strabismus surgery. After an
average follow-up period of 14 months, they discovered that
70% of the patients exhibited alignment within 10 pd of
esotropia or exotropia. Khan (4) described the results of eight
patients who underwent two-muscle horizontal rectus
surgery with a simultaneous intraoperative injection of BT
into the medial rectus. Six of these eight patients demon-
strated residual esotropia of less than 10 pd. This procedure
was therefore considered safe and effective, although a more
extensive study was suggested to be necessary to confirm the
findings. This author later expressed disappointment with
the results of a one-muscle injection of BT in the setting of a
maximal recession-resection procedure for very large con-
comitant esotropia and exotropia (unpublished data) and
attributed this result to poor vision in one eye (the original
motive for the monocular procedure) (13). In these three sets
of cases, it is not possible to predict how the outcomes may
have varied if the patients had undergone surgeries without
BT injections.
Two characteristics of the current study enhanced our
confidence with the results: the randomization of patients into
one of two treatment modalities and the similarity between the
two patient groups. These two factors helped to minimize the
effects of other variables on the outcomes. The groups were
similar in regards to visual acuity, frequency of amblyopia,
state of binocularity, pretreatment angle of misalignment, and
extent of surgery. Therefore, we believe that BT injection
would have been the main factor to account for any differences
between group outcomes, if any differences had been found.
It is possible that the incidence of transient ptosis could be
reduced by injecting the recess muscle several days prior to
surgery. Intact tissues not ruptured by surgery would hold
the toxin in the muscle belly, thereby preventing it from
spreading to adjacent tissues. The preoperative injection
could be performed while monitoring with electromyogra-
phy; also, some practitioners may waive the use of this
device (14-16).
Our reported incidence of transient ptosis (42%) was
higher than that in other studies. For example, Rowe and
Table 3 - Percent net changes in the postoperative deviations.
Post-operative interval
One day 7-15 days 30days 90 days $6 months
SG+BT 95.0¡16.2 (9) 109.6¡24.1 (11) 100.3¡17.5 (10) 83.4¡17.9 (9) 79.4¡15.7 (10)
SG 101.9¡19.9 (7) 92.3¡21.9 (9) 83.0¡17.6 (10) 71.4¡12.0 (6) 69.0¡16.5 (11)
p-value 0.63 0.15 0.05 0.19 0.10
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Noonan (17) reported an incidence of 8.4% for 511 patients
who were treated with 3 U of BT (injected into the
horizontal recti to treat different types of strabismus).
Additionally, Dawson and Sainani (18) reported an inci-
dence of 4% for 503 patients who were treated for secondary
strabismus. For studies that used intraoperative BT injec-
tions, Owens et al. (3) reported ptosis in two of three
patients, O¨zkan et al. (5) observed no ptosis in ten patients
who were treated intraoperatively with 5 U of BT, and Khan
(4) did not comment on ptosis in his study.
With regards to the dose-effect factor, a recent review of the
literature concluded that it is not possible to determine the
ideal BT dose-effect due to the different types and doses of
botulinum toxin that were used in published trials (19). We
chose to use 5 U per patient because this was the dose that
had most commonly been used by other authors and because
higher doses carry the risk of increased adverse effects (20).
None of the patients in this study had duction limitation
or lateral gaze diplopia, and none complained of a reduction
in their visual field. These three adverse effects, in addition
to exophthalmos, are typically expected when supramax-
imal plans are performed.
This study had several limitations. First, the physician
who assessed the patient outcomes was unaware of the
administered treatments during the data collection, except
for the evaluation of patients with ptosis. Although this
limitation was absent at the time of the final visit, the
potential for ascertainment bias could not be refuted,
despite efforts made to conduct an unbiased study.
As the treatment groups contained a mixture of esotropic
and exotropic patients, it would be interesting to include a
post-hoc analysis in each group (and in the eso- and
exotropia subgroups) to compare the efficacy of BT
administration. However, the frequency of BT-induced
ptosis prevented us from increasing the sample size to
make such a comparison, although other studies on the
usefulness of BT injection for strabismus treatment have
found no association between the reduction in the angle of
deviation and the type of deviation (20-22).
Based on the present findings, it appears that intraopera-
tive BT injection does not enhance the effect of monocular
horizontal deviation surgery. However, as this was a pilot
study, the sample size was small, and this may have masked
a real, albeit minor, therapeutic effect of intraoperative BT
injection.
This study was presented at the XVIII Congress of Latin
American Consul of Strabismus (CLADE) in November
2010.
This study was performed in the Clinical Hospital of the
State University of Campinas (UNICAMP) in Campinas, SP,
Brazil.
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